The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Relay Therapeutics Inc (RLAY) shows that investor sentiment remained same, with the stock’s consolidated last price to $8.40. The Relay Therapeutics Inc has recorded 12,230 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Relay Therapeutics to Participate in Stifel 2023 Healthcare Conference.
Relay Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Relay Therapeutics Inc is $1.04B. A total of 0.66 million shares were traded on the day, compared to an average of 1.16M shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, RLAY has seen 0 BUY and 8 SELL insider trades, representing the acquisition of 0 and the disposition of 9,614 shares. Over the last 12 months, there were 14 BUYs and 43 SELLs from insiders. Insiders purchased 736,930 shares during that period but sold 186,216.
In the most recent transaction, Bergstrom Donald A sold 3,451 shares of RLAY for 6.03 per share on Oct 30. After the transaction, the President, R&D now owns 235,033 company shares. In a previous transaction on Oct 30, Catinazzo Thomas sold 1,697 shares at 6.03 per share. RLAY shares that Chief Financial Officer owns now total 144,145.
Among the insiders who sold shares, Adams Brian disposed of 1,632 shares on Oct 30 at a per-share price of $6.03. This resulted in the Chief Legal Officer holding 129,961 shares of RLAY after the transaction. In another insider transaction, Rahmer Peter sold 1,354 shares at $6.03 per share on Oct 30. Company shares held by the insider now total 316,872.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for RLAY in the last 3 months, the mean price target is $23.03 with high estimates of $33.00 and low estimates of $9.40. In terms of 52-week highs and lows, RLAY has a high of $23.18 and a low of $5.95.
As of this writing, RLAY has an earnings estimate of -$0.76 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.7 per share and a lower estimate of -$0.79. The company reported an EPS of -$0.81 in the last quarter, which was 1.20% higher than expectations of -$0.82.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. RLAY’s latest balance sheet shows that the firm has $958.07M in Cash & Short Term Investments as of fiscal 2021. There were $22.90M in debt and $24.32M in liabilities at the time. Its Book Value Per Share was $6.32, while its Total Shareholder’s Equity was $897.81M.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RLAY is Buy with a score of 4.64.